ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 2761 - 2775 of 5115 products
Pharmaron Acquires US Phase I/II Clinical CRO from Shin Nippon
$5.00
Available
Chengdu's HitGen Licenses Cancer Drug Candidates to Cancer Research UK
$5.00
Available
CloudHealth Announces Genomic Immunotherapy Response Diagnostic
$5.00
Available
Xynomic Pharma In-Licenses Global Rights to HDAC Inhibitor for Cancer
$5.00
Available
Fudan-Zhangjiang Bio-Pharma Invests $2 Million in Adgero of the US
$5.00
Available
Qilu Pharma Launches Biosimilar to AstraZeneca's Iressa in China
$5.00
Available
Anxin Doctor, a Mobile Health App, Announces $28 Million Funding
$5.00
Available
Eisai In-Licenses China Rights for Two Parkinson's Drugs from Orion
$5.00
Available
Hong Kong's Ally Bridge Invests in Two European Biopharmas
$5.00
Available
BioSense Inks $68 Million Deal for Neovacs
$5.00
Available
Lee's Pharm to Market Solasia's Oral Mucositis Treatment in China
$5.00
Available
Hutchison MediTech Begins Phase II Study of Its PSC Drug Savolitinib in China
$5.00
Available
Genecast of Beijing Raises $18 Million for Cancer DNA Diagnostics
$5.00
Available
Aslan Pharma Reports Positive Data for HER-2 Cancer Drug
$5.00
Available
Shanghai's Abbisko Therapeutics Raises $28 Million for Cancer Drugs
$5.00
Available